In vivo effect of chronic administration of vasoactive intestinal peptide on gut-associated lymphoid tissues in rats.
The in vivo effects of chronic administration of vasoactive intestinal peptides (VIP) on the lymphoid cell traffic and the population and function of cells in intestinal lymph and gut-associated lymphoid tissues were examined in rats. VIP was continuously infused from the superior mesenteric artery in rats at a dose of 10 ng/min/kg body weight for 96 h. Lymphocyte transport through intestinal lymph was significantly reduced by VIP without any changes in lymph flow. When lymphocyte subpopulation was examined in intestinal lymph, T cell subsets were decreased with a dominant reduction in the population of helper T cells. T cell subsets were also decreased in mesenteric lymph nodes, but in this case suppressor/cytotoxic T cell subsets were mainly reduced. Despite of the decrease in lymphocyte transport through intestinal lymph and changes of lymphocyte subpopulation, proliferative response of lymphocytes from intestinal lymph and mesenteric lymph nodes to phytohemagglutinin did not show any significant alteration after administration of VIP. By histochemical study on the lamina propria of the small intestine, the population of pan T cells, especially helper T cells, was demonstrated to be significantly decreased after VIP treatment. There was also a marked decrease in the number of immunoglobulin (Ig) A-containing cells in the lamina propria of the small intestine in VIP-treated rats, while no significant changes were seen in the number of IgG and IgM-containing cells. Our present results showed the possibility that a long-term alteration of serum VIP levels could affect the dynamics of immune effector cells and IgA production in gut-associated lymphoid tissues.
Ohkubo
N
N
Department of Medicine, School of Medicine, Keio University, Tokyo, Japan.
Miura
S
S
Serizawa
H
H
Yan
H J
HJ
Kimura
H
H
Imaeda
H
H
Tashiro
H
H
Tsuchiya
M
M
D000818:Animals; D002465:Cell Movement / Q000187:drug effects; D007261:Infusions, Intra-Arterial; D007413:Intestinal Mucosa / Q000276:immunology*; D008196:Lymph / Q000166:cytology; D008198:Lymph Nodes / Q000166:cytology; D008213:Lymphocyte Activation / Q000187:drug effects; D016131:Lymphocyte Subsets / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects*; D008221:Lymphoid Tissue / Q000166:cytology / Q000187:drug effects*; D008297:Male; D017538:Mesenteric Artery, Superior; D051381:Rats; D017208:Rats, Wistar; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*
D014660:Vasoactive Intestinal Peptide